Podcasts about msd

Belief that both employers and the Government need to up their game to ensure Kiwis are being hired before migrants. The Immigration Minster's getting tougher on employers hiring more migrants than unemployed New Zealanders. Erica Stanford says employers will be stripped of the chance to recruit migrants if they're not looking closer to home. Business NZ Immigration Specialist Rachel Simpson told Ryan Bridge the Ministry need to help businesses prioritise Kiwis. She says employers will always look locally but immigration is about the skills those people bring to the country. LISTEN ABOVESee omnystudio.com/listener for privacy information.

In this Vet Times Extra podcast, Paul Imrie is joined by Stephen Maxwell, veterinary advisor from MSD Animal Health, to discuss some of the queries to MSD Animal Health's veterinary support line. SPONSORED Caninsulin has been a trusted brand for over 30 years and is used to treat diabetic cats and dogs. In the lead up to Pet Diabetes Month, we'll talk through some common queries from MSD Animal Health's Veterinary support service. MSD also offer a range of free diabetes resources designed to support practices and owners, as well as free diabetes CPD courses. To access these, visit the links below or contact your MSD Account Manager. https://www.msd-animal-health-hub.co.uk/ahp/caninsulin/tools https://msdchameleon.cordeo.net/ (printed materials) Stephen Maxwell is an MSD veterinary advisor and during the past year has been helping front-line veterinarians in the UK with their diabetic cases through technical product support. NOTE: All pets' names in this broadcast have been changed to protect identities. Caninsulin® 40 IU/ml Suspension for Injection contains porcine insulin. POM-V. Further information is available from the SPC, datasheet or package leaflet. Advice should be sought from the medicine prescriber. Prescription decisions are for the person issuing the prescription alone. Use Medicines Responsibly. © MSD Animal Health UK Limited. UK-NON-250900041.

What makes farmers change? And what holds them back? Our guest this week, Dr Ruth Nettle, has spent 25 years studying just that. Ruth has spent her career looking into how people in agriculture learn, adapt, and lead.Now leading the Rural Innovation Research Group at the University of Melbourne, Ruth has seen how agricultural extension, advisory networks, and rural communities have evolved through time. In this episode, she and Ferg chat about trust, workforce challenges, and what the future of extension looks like in a more commercial and tech-driven world.They talk about what makes a great employer in agriculture, why a positive team culture matters more than pay, and how farms can attract and retain staff in a global skills shortage. Ruth also shares her thoughts on AI in agriculture, the importance of human-to-human learning, and what Australia could take from extension systems overseas.If you work with farmers, lead a team, or care about the people side of farming, this episode offers great insight into agricultural workforce development, rural leadership, and the evolving role of extension in agriculture today.Head Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, and Heiniger Australia and New Zealand. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out Heiniger's product range HERECheck out the MSD range HERECheck out Allflex products HERE

Neste episódio do Agro Resenha Podcast, conversamos com Simone Rodrigues, publicitária e diretora executiva da Agência Make ID. Com raízes profundas no agro, nascida e criada na fazenda, compartilha como sua vivência desde cedo foi crucial para entender e atuar estrategicamente com grandes marcas do agro. Ela aborda a essência do relacionamento e da confiança no setor, a evolução da publicidade multicanal, e o crescente impacto da inteligência artificial e análise de dados para mensurar o ROI de campanhas. Descubra as tendências que moldarão a comunicação para o produtor rural nos próximos anos e a importância de uma estratégia que vá além da sacada, gerando verdadeiro engajamento. Uma conversa imperdível sobre paixão, credibilidade e o futuro do marketing no campo. PARCEIROS DESTE EPISÓDIO Este episódio foi trazido até você pela SCADIAgro! A SCADIAgro trabalha diariamente com o compromisso de garantir aos produtores rurais as informações que tornem a gestão econômica e fiscal de suas propriedades mais sustentável e eficiente. Com mais de 30 anos no mercado, a empresa desenvolve soluções de gestão para produtores rurais espalhados pelo Brasil através de seu software. SCADIAgro: Simplificando a Gestão para o Produtor Rural Site: https://scadiagro.com.br/Podcast Gestão Rural: https://open.spotify.com/show/7cSnKbi7Ad3bcZV9nExfMi?si=766354cb313f4785Instagram: https://www.instagram.com/scadiagro/LinkedIn: https://www.linkedin.com/company/scadiagroYouTube: https://www.youtube.com/channel/UCQxErIaU0zBkCAmFqkMohcQ Este episódio também foi trazido até você pela Nutripura Nutrição e Pastagem! A Nutripura, que tem como base valores como honestidade, qualidade e inovação nos produtos e excelência no atendimento, atua há mais de 20 anos no segmento pecuário, oferecendo os melhores produtos e serviços aos pecuaristas. Fique ligado nos artigos que saem no Blog Canivete e no podcast CaniveteCast! Com certeza é o melhor conteúdo sobre pecuária que você irá encontrar na internet. Nutripura: O produto certo, na hora certa. Site: http://www.nutripura.com.brBlog Canivete: https://www.nutripura.com.br/pub/blog-canivete/Instagram: https://www.instagram.com/nutripura/Facebook: https://www.facebook.com/Nutripura/LinkedIn: https://www.linkedin.com/company/nutripura/YouTube: https://www.youtube.com/user/TvNutripura INTERAJA COM O AGRO RESENHAInstagram: http://www.instagram.com/agroresenhaTwitter: http://www.twitter.com/agroresenhaFacebook: http://www.facebook.com/agroresenhaYouTube: https://www.youtube.com/agroresenhaCanal do Telegram: https://t.me/agroresenhaCanal do WhatsApp: https://bit.ly/arp-zap-01 ACOMPANHE A REDE RURAL DE PODCASTSSpotify: https://open.spotify.com/show/65JghRGLPnPT4vhSNOkjh7?si=7995dc4d17fa489bApple Podcasts: https://podcasts.apple.com/br/podcast/rede-rural-de-podcasts/id1467853035 E-MAILSe você tem alguma sugestão de pauta, reclamação ou dúvida envie um e-mail para contato@agroresenha.com.br QUERO PATROCINARSe você deseja posicionar sua marca junto ao Agro Resenha Podcast, envie um e-mail para contato@agroresenha.com.br FICHA TÉCNICAApresentação: Paulo OzakiProdução: Agro ResenhaConvidado: Simone RodriguesEdição: Senhor A - https://editorsenhor-a.com.brSee omnystudio.com/listener for privacy information.

“The key word is curiosity. That curiosity helps you to question and improve not only yourself, but also your processes, your systems, and how you interact with different stakeholders.”Jeroen Janssens, External Manufacturing Technical Operations Lead at MSD, provides insights through a technical lens on how one of the world's largest pharmaceutical companies approaches biologics manufacturing partnerships. With over 15 years of experience spanning validation engineering to director-level leadership, he oversees manufacturing of 11 biologics across Europe and Asia whilst pioneering AI-powered solutions for complex manufacturing challenges.In the latest PharmaSource podcast episode, Jeroen explains how curiosity-driven leadership, strategic CDMO partnerships, and emerging technologies are reshaping external manufacturing excellence at MSD.Read article

Neste episódio do Agro Resenha Podcast, conversamos com Simone Rodrigues, publicitária e diretora executiva da Agência Make ID. Com raízes profundas no agro, nascida e criada na fazenda, compartilha como sua vivência desde cedo foi crucial para entender e atuar estrategicamente com grandes marcas do agro. Ela aborda a essência do relacionamento e da confiança no setor, a evolução da publicidade multicanal, e o crescente impacto da inteligência artificial e análise de dados para mensurar o ROI de campanhas. Descubra as tendências que moldarão a comunicação para o produtor rural nos próximos anos e a importância de uma estratégia que vá além da sacada, gerando verdadeiro engajamento. Uma conversa imperdível sobre paixão, credibilidade e o futuro do marketing no campo. PARCEIROS DESTE EPISÓDIO Este episódio foi trazido até você pela SCADIAgro! A SCADIAgro trabalha diariamente com o compromisso de garantir aos produtores rurais as informações que tornem a gestão econômica e fiscal de suas propriedades mais sustentável e eficiente. Com mais de 30 anos no mercado, a empresa desenvolve soluções de gestão para produtores rurais espalhados pelo Brasil através de seu software. SCADIAgro: Simplificando a Gestão para o Produtor Rural Site: https://scadiagro.com.br/Podcast Gestão Rural: https://open.spotify.com/show/7cSnKbi7Ad3bcZV9nExfMi?si=766354cb313f4785Instagram: https://www.instagram.com/scadiagro/LinkedIn: https://www.linkedin.com/company/scadiagroYouTube: https://www.youtube.com/channel/UCQxErIaU0zBkCAmFqkMohcQ Este episódio também foi trazido até você pela Nutripura Nutrição e Pastagem! A Nutripura, que tem como base valores como honestidade, qualidade e inovação nos produtos e excelência no atendimento, atua há mais de 20 anos no segmento pecuário, oferecendo os melhores produtos e serviços aos pecuaristas. Fique ligado nos artigos que saem no Blog Canivete e no podcast CaniveteCast! Com certeza é o melhor conteúdo sobre pecuária que você irá encontrar na internet. Nutripura: O produto certo, na hora certa. Site: http://www.nutripura.com.brBlog Canivete: https://www.nutripura.com.br/pub/blog-canivete/Instagram: https://www.instagram.com/nutripura/Facebook: https://www.facebook.com/Nutripura/LinkedIn: https://www.linkedin.com/company/nutripura/YouTube: https://www.youtube.com/user/TvNutripura INTERAJA COM O AGRO RESENHAInstagram: http://www.instagram.com/agroresenhaTwitter: http://www.twitter.com/agroresenhaFacebook: http://www.facebook.com/agroresenhaYouTube: https://www.youtube.com/agroresenhaCanal do Telegram: https://t.me/agroresenhaCanal do WhatsApp: https://bit.ly/arp-zap-01 ACOMPANHE A REDE RURAL DE PODCASTSSpotify: https://open.spotify.com/show/65JghRGLPnPT4vhSNOkjh7?si=7995dc4d17fa489bApple Podcasts: https://podcasts.apple.com/br/podcast/rede-rural-de-podcasts/id1467853035 E-MAILSe você tem alguma sugestão de pauta, reclamação ou dúvida envie um e-mail para contato@agroresenha.com.br QUERO PATROCINARSe você deseja posicionar sua marca junto ao Agro Resenha Podcast, envie um e-mail para contato@agroresenha.com.br FICHA TÉCNICAApresentação: Paulo OzakiProdução: Agro ResenhaConvidado: Simone RodriguesEdição: Senhor A - https://editorsenhor-a.com.brSee omnystudio.com/listener for privacy information.

Mining Stock Daily welcomes Michael Green to delve into the broken equity structure and its profound implications for the metals and miners audience. Green outlines his serious concerns regarding the explosive growth of passive investing, estimating that north of 50% of the total market capitalization is now contained within passive vehicles. This structural change creates a passive mandate bias toward large-cap concentration, which specifically distorts the valuations and liquidity of smaller cap resource and precious metals stocks. He illustrates how incremental passive flows disproportionately magnify the price impact on the largest stocks while shrinking buy orders for smaller index components, creating a momentum reinforcement vehicle that exacerbates market bifurcation. The discussion also covers the dangers of highly leveraged instruments like 2x-3x ETFs and the motivations behind their creation, which often caters to speculative demand rather than thoughtful investment policy. Finally, Green links current financial behavior and political inaction to historical cycles, drawing an analogy between the contemporary failure of American systems and the collapse of the Roman Republic, suggesting the current gold rally may signal a flight from systemic risk rather than just inflation.Inquire more about the MSD discount for to Mike's Substack HEREThis episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠revival-dash-gold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠equinoxgold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Integra Resources is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

Host: Susanna Price Guest: Stephanie Schwarting Want to watch the episode? Go to: https://esc365.escardio.org/event/2176 Want to watch the extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests:  Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Arrhythmias in cardiac amyloidosis Taking the 'O' out of HOCM: managing LVOT obstruction Snapshots Host: Susanna Price Guests: Carlos Aguiar, Stephanie Schwarting, Ahmad Masri Want to watch that episode? Go to: https://esc365.escardio.org/event/2176 Want to watch that extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Ahmad Masri has declared to have potential conflicts of interest to report: research grants from Pfizer, Ionis, Attralus, Cytokinetics and Janssen. Consulting fees from Cytokinetics, BMS, BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Edgewise, Rocket, Lexeo, Prothena, BioMarin, AstraZeneca, Avidity, Neurimmune, and Tenaya. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

We discussed a few things including:1. Their career journeys2. Merck's venture strategy and GHIF story3. MSD Idea Studios4. CVC landscape and trends5. Outlook for pharma and innovationBill has led MSD Global Health Innovation (GHI) since 2010, playing a strong role in the US company's transition a decade ago from general consumer pharmaceuticals to a focus on biopharmaceuticals and oncology.With 45 portfolio companies and about 80% having commercial agreements with MSD, His approach of always seeking to understand and solve the parent company's core challenges has proven successful.Last year, the fund expanded beyond the US, launching two accelerator programms, one in Berlin covering central Europe and one in Singapore covering 10 Asian countries. The accelerators will also invest at an earlier stage than the growth stage-focused core GHI fund has typically done.Both in the US and abroad, GHI is focused on four key areas of pharma services: drug discovery, clinical development, supply chain and patient access.In drug discovery, Bill is particularly excited about AI and machine learning allowing drugs to be identified faster.  The fund has invested in about 12 companies applying AI to biology, chemistry and vaccines in the past two years, with a belief that these technologies are on the cusp of a breakthrough.Clinical development is another critical focus, especially in patient diversity and trial management.The unit is also exploring supply chain innovations, with systems tracking raw materials coming in and finished goods going out, much like a “control tower at an airport”.A veteran of the venture capital sector, Bill maintains that corporate venture capital is becoming increasingly sophisticated.  He believes corporate venture capital has now established itself as “part of the ecosystem of investing” and offers unique value that traditional investors cannot.----Joel is a seasoned executive with extensive experience in venture investments and strategic innovation within the healthcare sector.  With a career spanning over two decades, he has held pivotal roles at renowned organizations like Merck, J&J, and JPMorgan, focusing on biotech, corp dev and health equity.  He excels in bridging the gap between life sciences and digital health technology.  He is a recognized advocate for diversity and inclusion, emphasizing health equity in his professional endeavors.  #podcast #afewthingspodcast

Want to know more about meat-eating quality traits like IMF, shear force and marbling? Our guest this week, Dr Peter McGilchrist, is a leading meat scientist and professor at the University of New England, Australia, likely has the answers you're looking for. Peter and Mark talk all things meat-eating quality and how the red meat industry can move beyond commodity pricing by identifying premium quality products through genetics, processing, and proper animal handling. Peter and Mark discuss the importance of keeping an eye on IMF and shear force so that lamb doesn't "end up like pork," as well as the importance of early marbling and how we can genetically impact all three of these things. Pete also treats us to a quick biochemistry lesson explaining the science of cold-shortening as well as insights on recent trial work he's been involved with on the impacts of feeding sheep pre-slaughter on eating quality.This podcast is a masterclass on the various aspects of red meat eating quality and is one not to miss! Head Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, and Heiniger Australia and New Zealand. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out Heiniger's product range HERECheck out the MSD range HERECheck out Allflex products HERE

O mercado pet está passando por uma revolução impulsionada pelas inovações tecnológicas.Neste episódio, conversamos com Tatiana, da MSD, sobre como dispositivos inteligentes, aplicativos de monitoramento de saúde e serviços personalizados estão transformando o cuidado com os animais de estimação.Durante a conversa, abordamos temas como:- Coleiras inteligentes com GPS e sensores de saúde- Aplicativos de acompanhamento veterinário- Comedouros e bebedouros automatizados- Telemedicina veterinária- Dispositivos interativos- Produtos sustentáveis e alimentação personalizadaEssas tecnologias estão redefinindo a forma como tutores e profissionais veterinários cuidam dos animais, promovendo mais segurança, bem-estar e qualidade de vida.O episódio também destaca a importância da atualização profissional e o crescimento do setor, que já conta com iniciativas como o MBA em Mercado Pet da USP.Hosts: @patricia.mosko | @rebecabacchiBicho é bicho, gente é gente... mas bicho e gente é família! ❤️Estamos aqui para acolher e auxiliar responsáveis, alunos recém-formados, profissionais atuantes na veterinária e todos os apaixonados por pets.Afinal, eles são mais do que animais de estimação — são parte da nossa família. É essa paixão que nos move todos os dias na missão de levar informação, cuidado e amor aos lares multiespécie.

Lukáš Janáč je zakladatel architektnonické kanceláře YUAR architects. Ateliér YUAR architects je předním českým ateliérem zabývajícím se návrhy i projektovým řízením realizace kancelářských prostor. Má za sebou přes 500 projektů, za které získal řadu českých i mezinárodních ocenění.Kanceláře od ateliéru YUAR mají například Česká spořitelna, Porsche ČR, MSD nebo Siemens, který je s plochou přes 20 000 m2 jedním z největších projektů v České republice. Tvorbu YUAR architects si prohlédněte na www.yuar.eu

Ever wished you could get breeding values on your commercial Merinos without having to record weights, dates or pedigrees?This week, we're launching neXtPredict, our brand new genomic tool that lets you go straight from DNA to breeding values with just a simple TSU sample.Developed in partnership with Weatherbys Scientific, neXtPredict provides base genomic breeding values, parentage, poll/horn testing and a flock profile for Merino breeders. It's powered by the MerinoSelect database and backed by MLA-funded research through AGBU and Sheep Genetics.To announce the launch this week on the podcast, Ferg chats with Tamarah Luxton, Territory Manager at Weatherbys Scientific. Tamarah shares the story of Weatherbys' journey from managing thoroughbred pedigrees in Ireland to providing cutting-edge genomic testing for livestock across Australia. neXtPredict has three service tiers, designed to suit everyone from large commercial breeders to data-driven operations wanting deeper insights.CORE gives you access to the neXtPredict Portal, where you can view gBVs, parentage, poll/horn, flock profiles and indexes, and filter or rank animals on standard industry indexes or generic neXtgen Agri indexes.PLUS includes everything in CORE, plus trait correlation analysis, the creation of custom indexes, and one-on-one support from the neXtgen Agri team.PRO adds long-term data storage, the ability to include non-genomic traits (like wool quality or dag scores), view multi-year data, and work directly with our consultants on testing strategies and optimisation.If you are interested in using neXtPredict, get in touch with us here at neXtgen Agri:info@nextgenagri.comOr with Weatherbys Scientific:tluxton@weatherbys.com.auHead Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, and Heiniger Australia and New Zealand. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out Heiniger's product range HERECheck out the MSD range HERECheck out Allflex products HERE

MSD welcomes Bill Fleckenstein of Fleck Capital to dive into the markets, addressing the big sell-off in precious metals that followed Gold running up to $4,000 and Silver hitting $50. They explore the confusing narrative behind gold's recent outperformance, noting that its surge came despite events seeming "less bad" incrementally, suggesting it is catch-up and anticipation of future policy. Fleckenstein focuses on the risk of presidential control over the Federal Reserve, predicting policies like yield curve control, which he believes will likely be "negative for the dollar" and lead to "more inflation". This discussion leads to an analysis of the dangers posed by the desire of the "powers that be" to "run the economy hot," which inevitably leads to inflationary consequences and the dangerous misallocation of capital. Finally, they analyze the nature of the immediate correction, the hard sell-off experienced by the miners, and the philosophical debate over government acquisition of equity in critical mineral companiesOur second segment features Tom Woolrych with his keen eye to detail and 3D modeling of exploration stories. Tom walks through a few specific companies making headlines lately. You can watch that interview and his presentation HERE.This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠revival-dash-gold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠equinoxgold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Integra is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

Warwick Smith of American Pacific Mining connected with MSD's Michael McCrae to discuss the upcoming drill campaign at the Madison copper-gold porphyry project in Montana. Having now received a key drill permit in early October, this next phase of drilling will test large-scale porphyry and high-grade skarn targets with step-outs and deeper holes guided by decades of geologic mapping, geochemical sampling, geophysical surveying, and 3D structural modeling.

Host: Susanna Price Guest: Rudolf de Boer Want to watch that extended interview on AI in echocardiography? Go to: https://esc365.escardio.org/event/2175?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: the institution of Rudolf de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Rudolf de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Rudolf de Boer received travel support from Abbott and NovoNordisk. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Visceral adiposity: paradigm shift in HFpEF management Artificial Intelligence in echocardiography Milestones: ISIS-2 Host: Susanna Price Guests: Carlos Aguiar, Milton Packer, Rudolf de Boer Want to watch the episode? Go to: https://esc365.escardio.org/event/2175 Want to watch the extended interview on AI in echocardiography? Go to: https://esc365.escardio.org/event/2175?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: the institution of Rudolf de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Rudolf de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Rudolf de Boer received travel support from Abbott and NovoNordisk. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Barry Knapp of Ironsides Macro joined MSD today to provide his thoughts on why the last 25 bps cut by the FOMC under-shot the target to save small business, bank and the housing market. Barry also dives into some important data about the weakening labor market and historical data on capex buildout in the current economy.

What do you get when three sheep consultants, all podcast hosts, from Australia, England and Wales sit down in front of a microphone? You get a very entertaining, slightly chaotic, sheepy podcast!This week, we're joined by Liz Genever and Nerys Wright to discuss the launch of OptiEwe UK as well as the challenges and opportunities faced by farmers over there. Liz, Nerys and Ferg chat about this summer's extremely dry weather, current lamb prices, shifts in farming practices (and the role of genetics in those shifts), as well as the difficulties of the ever-changing government policies.Liz and Nerys are launching OptiEwe UK next week, and we're excited to continue working with them over the next few years! Tune into their podcast by searching "The Sheep Geeks". You can catch their episode with Mark here: https://podcasts.apple.com/gb/podcast/episode-11-talking-to-mark-ferg-ferguson-about-optiewe/id1777227463?i=1000726635865.If you're interested in starting or attending an OptiEwe discussion group in New Zealand, get in touch with Sophie at sophie@nextgenagri.com.Head Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, and Heiniger Australia and New Zealand. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out Heiniger's product range HERECheck out the MSD range HERECheck out Allflex products HERE

La directora médica de MSD para el Clúster Norte, explicó cómo prevenir y detectar el VPH. Las cifras de contagios en Colombia son alarmantes.See omnystudio.com/listener for privacy information.

Mining Stock Daily is thrilled to announce well-known resource reporter, Michael McCrae, is joining MSD as a new correspondent. We welcome Mike into the channel today. We have new drill results to report from Stellar AfricaGold, Intrepid Metals and Aton Resources. Fortuna Mining launch a new JV exploration deal with DeSoto. Both Collective Mining and NexGen announce financings. This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠revival-dash-gold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠equinoxgold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Integra is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

Dr. Monty Pal and Dr. Matteo Lambertini discuss a compelling global study on the clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers, the association of pre-diagnostic awareness of BRCA status with prognosis, and the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants. TRANSCRIPT Dr. Monty Pal: Well, hello everyone, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles. Now, when we think about genetic testing, whether for patients diagnosed with breast cancer or for other family members of them, it seems to be widely underutilized. Today, we're going to be discussing a recently published study in the Journal of Clinical Oncology that reported on the clinical behavior of breast cancer and specifically young BRCA1 and BRCA2 carriers, and the association of pre-diagnostic awareness of BRCA status with prognosis. I thought this was just a fascinating piece, and I honestly couldn't wait to have this conversation. It's a really compelling paper that highlights the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants, and really the need for genetic counseling and testing to inform people about early detection that could lead to a better prognosis. I'm really delighted to welcome the study's lead author, Dr. Matteo Lambertini. He really needs no introduction. He's very well known in the breast cancer world for his amazing contributions to fertility in the context of breast cancer, to pregnancy in the context of breast cancer, and genetic testing. He's an associate professor at the University of Genova, and a breast cancer medical oncologist at the San Martino Polyclinic Hospital in Genova, Italy.  Dr. Lambertini, thank you so much for joining us today. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a great pleasure. Dr. Monty Pal: Oh, thanks. And just FYI, if you're listening in and you want to hear our disclosures, they're all listed at the transcript of this podcast.  So, I poured through this paper [Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status] yesterday, Dr. Lambertini, and first of all, congratulations on this study. This was a huge international multicenter effort, 4,752 patients. How did you pool all these patients with young breast cancer? Dr. Matteo Lambertini: Thanks a lot for the question. Yes, this was an effort made by several centers all over the world. The main idea behind the creation of this network that we have named as BRCA BCY Collaboration, was to get as many data as possible in a sort of niche patient population in the breast cancer field, meaning women diagnosed with breast cancer at the age of 40 years or younger, and all of them being BRCA carriers. We know that around, in the Western world, around 5% of breast cancer cases are being diagnosed under the age of 40 years, and among them around 10-15% are BRCA carriers. So, I would say it's a relatively rare patient population where we did not have a lot of evidence to support our choices in terms of counseling on treatment, prevention, and oncofertility as well. That was the idea behind the creation of this network that includes many centers. Dr. Monty Pal: Yeah. You know, what's so interesting about this is that you sort of draw this line between patients who have BRCA testing at the time of diagnosis and then BRCA testing earlier in their course and then leading to a diagnosis perhaps. And I think that's where really sort of the dichotomy in outcome sits. Can you maybe elaborate on this and tell us about timing of genetic testing in this study and what that meant ultimately in terms of prognosis? Dr. Matteo Lambertini: In this specific analysis from this large network, including almost 5,000 women with breast cancer diagnosed at the age of 40 years or younger and being a BRCA carrier, we looked specifically into the timing of genetic testing because this is a retrospective study and the criteria for inclusion are those that I have just mentioned, so diagnosis at a young age plus carrying germline BRCA pathogenic or likely pathogenic variant. In this analysis, we have looked into the time the patient has got the genetic testing and particular we focused on two populations: those that were diagnosed, knowing already to be a BRCA carrier, and those that got tested after being diagnosed with breast cancer. And the main findings from this analysis have been that knowing to be a BRCA carrier was associated with a lower stage at the time of diagnosis, meaning more T1 tumors, so a tumor less than 2 cm, more node-negative disease, and this translated into less aggressive treatment, so less often axillary dissection, less often use of chemotherapy and anthracycline-based chemotherapy. And even more importantly, we have seen a better overall survival for those patients that were diagnosed already knowing to be BRCA carriers as compared to those tested after breast cancer diagnosis. These results after adjusting for all the confounding, stage, treatment and so on, there was not significant anymore, meaning that it's not the timing of test per se that is probably leading to a better survival, but it is the fact that knowing to be a BRCA carrier would likely translate into having access to all the preventive measures that we have in this setting and this will translate into an overall survival benefit, so in terms of saving more lives in young BRCA carriers. Dr. Monty Pal: I think it's such an important point, and it's one that I think might sound implicit, right, but it needs to be proven, I think, through a study like this. You know, the fact that finding this early, identifying the mutation, doing enhanced screening, and so forth, is really going to lead to superior clinical outcomes. One of the things that I think many people puzzle over, including myself, is what to do? I personally occasionally will see BRCA altered patients in the context of prostate cancer. But that's a very different population of individuals, right? Typically older men. In young females with BRCA mutation, I guess there's a specific set of considerations around reproductive health. You'd already highlighted preventive strategies, but what sorts of things should we be talking about in the clinics once a patient's diagnosed and once perhaps their breast cancer diagnosis is established? Dr. Matteo Lambertini: Yes, exactly. Knowing to be a BRCA carrier has a lot of implications from prevention to treatment to survivorship issues including reproductive counseling. And this is important not only for the patient that has been diagnosed with breast cancer but also for all the family members that will get tested and maybe identify with this sort of genetic alteration before diagnosis of cancer. Why this is important is because we have access to very effective preventive measures, a few examples: MRI screening, which starts at a very young age and normally young women don't have an effective screening strategy outside the BRCA field. Also, primary preventive measures, for example, risk-reducing surgery. These women are known to have a high risk of breast cancer and high risk of ovarian cancer. So the guidelines are suggesting to undergo risk-reducing salpingo-oophorectomy at a young age, so 35 to 40 years in BRCA1 carrier, 40 to 45 years in BRCA2 carrier. And also risk-reducing mastectomy should be discussed because it is a very effective way to prevent the occurrence of breast cancer. And in some situations, including the setting that we are talking about, so young women with breast cancer, BRCA carrier, also risk-reducing mastectomy has shown to improve overall survival.  On the other side, once diagnosed with breast cancer, nowadays knowing to be or not a BRCA carrier can make a difference in terms of treatment. We have PARP inhibitors in the early setting, in the adjuvant setting as well as in the metastatic setting. And in terms of survivorship implication, one of the critical aspects for young women is the oncofertility care which is even more complicated when we talk about BRCA carriers that are women candidates for gynecological surgery at a very young age. So this sort of counseling is even more complicated. Dr. Monty Pal: One of the other things, and this is subtle in your paper and I hope you don't mind me bringing it up, is the difference between BRCA1 and BRCA2. It really got me thinking about that because there are differences in phenotype and manifestation. Do you mind just expanding on that a little bit for the audience because I think that's a really important reminder that you brought up in the discussion? Dr. Matteo Lambertini: The difference between BRCA1 and BRCA2 carriers has been known that there are different phenotypes of breast cancer that are more often diagnosed in these two different populations. Normally BRCA1 carriers have a higher likelihood to develop a triple negative breast cancer as compared to BRCA2 carriers, more likely to develop a hormone receptor-positive HER2-negative disease. In this study, again, a specific population of young women with breast cancer, we have seen the same findings, mostly triple negative disease in BRCA1 carrier, mostly luminal-like disease in BRCA2 carrier. But what's novel or interesting from this study is to look also at the age at the time of diagnosis of this disease. And particularly in BRCA1 carriers, we should be sort of more careful about diagnosis of breast cancer and also other primary tumors including ovarian cancer because the risk of developing these malignancies is higher even at a younger age as compared to BRCA2 carriers. And this has implications also in the primary and secondary prevention that we were talking about earlier. Dr. Monty Pal: Oh, interesting. I guess the fundamental question then from your paper becomes, how do we get at the right patients for screening for BRCA1 and BRCA2? And I realize our audience here is largely oncologists who are going to be listening to this podcast, oncology providers, MDs, nurses, etc. But maybe speak for a moment to the general practitioner. Are there things that, for instance, a general practitioner should be looking for to say, “Wait a minute, this patient's high risk, we should consider BRCA1, BRCA2 testing or germline screening”? Dr. Matteo Lambertini: Yes, it's a very important question for the breast cancer community. After the updated ASCO guideline, the counseling is way easier because right now the age cutoff goes up to 65 years, meaning that all the patients diagnosed with breast cancer below the age of 65 years should be tested these days. And then above the age of 65, there are different criteria like triple-negative disease or family history. From a general practitioner standpoint, it's of course a bit more difficult, but knowing particularly the family history of the person that they have in front will be crucial to know if there are cases of breast cancer diagnosed at a young age, maybe triple-negative cases, knowing cases of ovarian cancer in first-degree relatives or pancreatic cancer in first-degree relatives, and of course cases of prostate cancer as well. So, I would say probably mostly the family side will be important from a general practitioner perspective.  From an oncology one, the other point that I think is important to stress also based on the data that we have shown in this publication is that having a case of breast cancer known to carry a BRCA pathogenic or likely pathogenic variant. It means that all the people around this case should get tested and if found to be BRCA carrier and healthy carrier, these people should also undergo the primary and secondary prevention strategies because this is very critical also to improve their outcomes and try to avoid the developing of breast or ovarian cancer, but also in the case of diagnosis of this disease, a diagnosis at an earlier stage, as we have seen in this paper. Dr. Monty Pal: Brilliant. I'm going to diverge from our list of questions here and close by asking a question that I have at the top of my mind. You're very young. I know our podcast listeners can't see you, but you're very, very young. Dr. Matteo Lambertini: Thank you. Thank you for that. Not so young but yeah. Dr. Monty Pal: You have nearly 300 papers. Your H-index is 67. You've already made these seminal contributions, as I outlined it from the outset, regarding fertility, regarding use of GnRH analogs, regarding pregnancy and breast cancer. What are you studying now? What are you really excited about right now that you're doing that you think might potentially be practice changing? Give us a little teaser. Dr. Matteo Lambertini: Yeah. Thanks a lot, Dr. Pal. Receiving this compliment from you is fantastic. So, thanks a lot for that. From my side, in terms of my research, I've been interested in the field of breast cancer in young women since the start of my training. I've had very good mentors from Italy, from Europe, from the U.S. I'm still interested in this field, so I think we still have a lot to learn to try to improve the care of young women with breast cancer. For example, the oncofertility care, which is something I worked a lot over the past years. Now with all the new treatment options, there's a sort of new chapter of oncofertility counseling. So, what's the impact of immunotherapy? What's the impact of the new targeted agents?  More on the genetic aspects, now we know that there's not only BRCA1 or BRCA2. There are a lot of other different genes that may increase the risk of breast cancer and other malignancies. And also for these genes, we really don't have a lot of evidence to counsel women on prognosis, treatment, prevention strategy. So we need to learn way more for this special patient population that are quite rare, and so we really need a multicenter academic effort to try to give some evidence in this field. Dr. Monty Pal: Yeah. It's tough because these are rare circumstances, but, you know, I think that you've done really well to sort of define some collective experiences that I think really define therapy. I mean, I just remember when I was in training 25 years ago, just reading through textbooks where all the experience around breast cancer and pregnancy was really just very sort of anecdotal almost, you know? And so it's great to see that the state of the science has moved forward.  Well, gosh, I really enjoyed our conversation today. I think your study really reminds us how powerful genetic information is in terms of improving outcomes. And, you know, hopefully this will lead some individuals to perhaps test more broadly in appropriate settings. So, thank you so much, Matteo, for joining us today with your fantastic insights on the ASCO Daily News Podcast. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a real pleasure. Dr. Monty Pal: And thanks to our listeners too. You'll find a link to Dr. Lambertini's study in the transcript of this episode. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks a ton. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Sumanta (Monty) Pal  @montypal  Dr. Matteo Lambertini @matteolambe   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Monty Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Matteo Lambertini: Consulting or Advisory Role: Roche, Novartis, Lilly, AstraZeneca, Pfizer, MSD, Exact Sciences, Gilead Sciences, Seagen, Menarini, Nordic Pharma Speakers' Bureau: Takeda, Roche, Lilly, Novartis, Pfizer, Sandoz, Ipsen, Knight Therapeutics, Libbs, Daiichi Sankyo, Gilead Sciences, AstraZeneca, Menarini, AstraZeneca, Menarini Research Funding (Inst.): Gilead Sciences Travel, Accommodations, Expenses: Gilead Sciences, Daiichi Sankyo Europe GmbH, Roche

Episode 2 of our monthly GU Cast Journal Club and today we focus on two key papers from recent times - the TRANSLATE trial of transperineal vs transrectal biopsy, and Keynote-564 on the role of adjuvant pembrolizomab following nephrectomy.   After great feedback from last month's launch episode, we are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Melbourne, AUS), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and  Declan Murphy Links to papers and previous podcasts below:1. Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial Lancet Oncology 2025GU Cast on TRANSLATE 2. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma NEJM 2024GU Cast on K-564 OS paper GU Cast Journal Club is supported by our Partner, MSD, through an unrestricted educational grant.Even better on our YouTube channelAbout GU Cast Journal Club:Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology. The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner. The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.

Is drench resistance an issue on your property? Thanks to modern technology, we have tools at our disposal to help.This week's guest is Ryan Luckman, vet and founder of DAGI, (Drench and Grazing Integration), an app that displays the risk of larval challenge/resistance risk for the paddocks on your farm, helping you make better grazing decisions. With the help of industry experts and the support of B+LNZ, Ryan has been building the DAGI (Drench And Grazing Integration) app over the past 2 years. Ryan talks us through the app and how it works on farm, as well as discussing the state of drench resistance in New Zealand. He and Ferg also discuss the topic of refugia and how this is all about the genetics of the worm population on your farm. Take a look at DAGI here:https://www.dagi.nz/why-dagiHead Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, and Heiniger Australia and New Zealand. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out Heiniger's product range HERECheck out the MSD range HERECheck out Allflex products HERE

It's been a busy (and meaningful) stretch for us these past few weeks! In this episode, we take you behind the scenes of our latest adventures across Michigan — from savoring local flavors at the Taste of Generosity event in Royal Oak to celebrating our 20th wedding anniversary (20 years!) at a Detroit Tigers game, complete with accessibility wins at Comerica Park. But our travels didn't stop there. We also traveled to Lansing for MS State Action Day, where we met with lawmakers to advocate for solutions to medical debt, a critical issue for many in the MS community. Additionally, we share updates from our recent neurology appointment in Ann Arbor, including how a small medication adjustment made a significant difference in Dan's sleep and daily life. Join us as we reflect on the power of self-care, the importance of caregiver support, and how embracing each moment keeps us moving forward together. Here are the links we referenced that offer depth and insights for our conversation: • Epic in-state journeys from baseball @ Comerica to lawmakers @ the Capitol – Our blog photo essay that highlights the moments we discuss in this episode. • Episode 84 – Taking on MSd with the Wrong MFR – Link to the podcast episode featuring our conversation with Adam Powell, one of the many friends we a chance meeting with at Taste of Generosity. ***** Remember to rate, review and subscribe to A Couple Takes on MS Podcast for two insightful perspectives on this one multifaceted disease.

Neste programa, olhamos para alguns dos temas que marcaram a semana. Na Guiné-Bissau terminou o prazo para a apresentação de candidaturas às eleições de 23 de Novembro, com a candidatura do PAI-Terra Ranka a ser indeferida por parte do Supremo Tribunal. Domingos Simões Pereira exortou o Supremo Tribunal de Justiça a "corrigir o erro cometido”. Em Angola, cinco organizações da sociedade civil instaram as Nações Unidas a liderarem uma investigação internacional sobre as mortes que ocorreram durante a greve dos taxistas. Em Moçambique, o Presidente da República pediu às Forças de Defesa e Segurança “estratégias para incinerar” o terrorismo. Começamos com a Guiné-Bissau, onde quase duas dezenas de candidaturas foram apresentadas às eleições de 23 de Novembro, de acordo com as intenções divulgadas até ao final do prazo, nesta quinta-feira. O histórico PAIGC corre o risco de, pela primeira vez, ser afastado de eleições, depois de o Supremo Tribunal de Justiça ter rejeitado a candidatura da coligação PAI-Terra Ranka às próximas presidenciais e legislativas da coligação que venceu com maioria absoluta em 2023 e foi afastada do poder com a dissolução do parlamento pelo Presidente, Umaro Sissoco Embaló. Esta sexta-feira, em conferência de imprensa, o líder do PAIGC, Domingos Simões Pereira, exortou o Supremo Tribunal de Justiça a reverter a exclusão da candidatura e a "corrigir o erro cometido”. Na quarta-feira, o candidato presidencial da coligação, Domingos Simões Pereira, falou com a  RFI e deixou um aviso: “Ou participamos nestas eleições ou se está a convocar o país para algo de terrível.” Quanto às outras candidaturas, Hugo Correia, em serviço especial para a RFI, fez-nos o resumo. O actual chefe de Estado, Umaro Sissoco Embaló, recandidata-se apoiado pela Plataforma Republicana "Nô Kumpu Guiné", que também viu a candidatura rejeitada, a 16 de Setembro, mas que acabou por ser aprovada depois de corrigidas as irregularidades apontadas pelo Tribunal. O antigo Presidente da Guiné-Bissau José Mário Vaz anunciou que volta a candidatar-se ao cargo, que perdeu para Sissoco Embaló em 2019. José Mário Vaz desvinculou-se do MADEM G-15 e é apoiado pelo COLIDE-GB (Convergência Nacional para a Liberdade e o Desenvolvimento da Guiné-Bissau). Na corrida às eleições, outra coligação, a API Cabas Garandi, que perdeu a maioria dos protagonistas que se tinham juntado em protesto contra o regime do Presidente Embaló. A coligação foi fundada por Braima Camará, depois de o MADEM G-15, que fundou com Sissico Embaló, se ter divido em duas alas, a que apoiava a sua direcção e a que estava com o Presidente da República. O mesmo aconteceu com outro dos fundadores, Fernando Dias, que ficou com uma ala do Partido de Renovação Social (PRS), fiel ao chefe de Estado. Na coligação estava ainda Nuno Gomes Nabiam, antigo primeiro-ministro que, a poucos dias do fim do prazo para a apresentação de candidaturas, deixou a coligação Cabas Garandi e anunciou que volta a concorrer a Presidente da República, apoiado pelo partido que dirige, a Assembleia do Povo Unido - PARTIDO Democrático da Guiné-Bissau (APU-PDGB). Braima Camará foi o primeiro a sair da API Cabas Garandi, depois de ter sido nomeado em agosto primeiro-ministro do Governo de iniciativa presidencial. Fernando Dias, do PRS, avança pela coligação e disse publicamente que nada o impedirá de ser candidato a Presidente da República. Outro membro e deputado do PRS, Siga Batista, entregou também no Supremo Tribunal de Justiça a candidatura às eleições presidenciais. João Bernardo Vieira, ex-secretário de Estado dos Transportes e Comunicações e dirigente do PAIGC, também se candidata à presidência. Nas candidaturas às presidenciais, encontra-se também o antigo primeiro-ministro, Baciro Djá, pela Frente Patriótica para a Salvação Nacional (Frepasna), e o presidente do Partido Aliança para República, Mamado Iaia Djaló. No último dia do prazo, entregaram ainda candidaturas o Partido Movimento Social Democrático (MSD), o Partido do Povo (PDP), o Partido Social dos Trabalhadores (PST), o Partido Unido Social Democrático (PUSD) e o candidato Independente Mamadu Embaló.))   Em Moçambique, os grupos armados em Cabo Delgado, no norte do país, continuam a atacar aldeias, raptar civis e saquear comunidades para sustentar a sua máquina de guerra. O Presidente da República, Daniel Chapo, pediu às Forças de Defesa e Segurança “estratégias para incinerar” os grupos insurgentes. Oiça o trabalho de Orfeu Lisboa, o nosso correspondente. Em Angola, cinco organizações da sociedade civil instaram as Nações Unidas a liderarem uma investigação internacional independente sobre as mortes que ocorreram durante a greve dos taxistas. As ONG´s predispõem-se a fornecer documentação para apoiar a busca por justiça. Francisco Paulo, o nosso correspondente, fez-nos o relato. Angola enfrenta, ha nove meses, um surto de sarampo em larga escala, com um registo de mais de 6 mil casos. Luanda, Uíge, Bié e Lunda-Sul são as regiões mais afectadas devido à falta de cobertura vacinal de rotina. A coordenadora do Programa Nacional de Imunização, Alda de Sousa, admitiu que a falta de cobertura vacinal de rotina para travar esta doença tem contribuído para o aumento de casos. Em Cabo Verde, o sector da Justiça melhorou em 2024, mas continua lento, admitiu o Procurador-Geral da República, Luís Landim. No sector da educação, a primeira-dama, Débora Katisa Carvalho, mostrou-se preocupada com a diminuição de rapazes no sistema de ensino e apelou, também, às famílias para promoverem uma educação mais equitativa e inclusiva, como nos contou Odair Santos. Em São Tomé e Príncipe, escolas em várias localidades estão a registar uma diminuição significativa no número de alunos, contou-nos o nosso correspondente Maximino Carlos. Na cultura, o coreógrafo e bailarino moçambicano Ídio Chichava esteve em destaque na Bienal de Dança de Lyon, em França, considerada como o principal evento de dança contemporânea do mundo. Ídio Chichava  apresentou um espectáculo participativo feito com o público e também o espectáculo “Vagabundus”. Oiça aqui.

This episode covers: Cardiology This Week: A concise summary of recent studies Strategic decisions in valvular heart disease Optimising drug therapy in chronic coronary syndromes Mythbusters: Does wearing a white coat make you smarter? Host: Susanna Price Guests: John-Paul Carpenter, Fabien Praz, Robert Storey Want to watch that episode? Go to: https://esc365.escardio.org/event/2092 Want to watch that extended interview on Optimising drug therapy in chronic coronary syndromes ? Go to: https://esc365.escardio.org/event/2092?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel, Fabien Praz and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: Robert Storey Want to watch that extended interview? Go to: https://esc365.escardio.org/event/2092?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Ben Pullinger of ATEX Resources joined MSD to discuss the updated mineral resource estimate for the Valeriano Project in Chile, which now includes the mineralization from the latest addition of the B2B Zone. The company also announced a new surface rights agreement surrounding the project. Ben talks about the importance of this agreement and what it means for the continued development.

Hedgefund Telemtry's Thomas Thornton joined MSD today for some general market commentary. Tommy discuss the gold move and how he's seeing the charts today as the market provides a little bit of a pullback.

Thousands of you listen to the podcast every week, but we've come to realise many of you don't know exactly what we do here at neXtgen Agri. In this episode, Mark, our host and CEO, takes to the mic and chats about all things neXtgen Agri and the services we provide to farmers across the globe. He shares how “farming in our hearts, science in our heads” drives everything we do.From helping farmers lift genetic gain to building tools that make breeding decisions clearer and faster, Ferg goes through the work that keeps our team busy. We're out in the yards and around kitchen tables across Australia and New Zealand, as well as in meetings and boardrooms for multiple industry bodies, helping provide the knowledge transfer bridge between farmers and scientists.If you have ever wondered what neXtgen Agri is really about, this is the episode that explains it all.Head Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, and Heiniger Australia and New Zealand. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out Heiniger's product range HERECheck out the MSD range HERECheck out Allflex products HERE

Elemental Altus Royalties and current CEO, Frederick Bell, sits down with MSD to chat about the announced merger with EMX Royalties. The deal is being back by new board members from Tether and will create a new mid-tier royalty company in the mining space. Fred discusses the merging of business strategies and cultures in the new company.

Arizona Sonoran Copper's George Ogilvie spoke with MSD last week at the Beaver Creek Precious Metals Summit. He emphasizes the two important catalysts approaching for the Cactus Project in Arizona. First, the company's updated mineral resource estimate (recently published) and then the Preliminary Feasibility Study to follow.

Luke Alexander of Newcore Gold joined Trevor at the MSD studio in Beaver Creek to provide some thoughts on the conference. Luke provides some details into the general themes he's saw at the conference along with ideas of questions he received in his meetings.

Daniel Earle joined MSD for an introduction to Highlander Silver. Highlander Silver is primarily focused on advancing the bonanza grade San Luis gold-silver project that is located adjacent to the past-producing Pierina mine in Central Peru. San Luis hosts Indicated Mineral Resources of 356 koz Au at 24.4 g/t Au and 8.4 Moz Ag at 579 g/t Ag and ranks among the 10 highest grade projects globally in both gold and silver categories. ** Today, Highlander published those new drill results which were highlighted with 24.8m at 7.43 g/t Au and 16.45 g/t Ag.

Our guest this week is Vicky Alexandrou, co-founder of Woven Optics.Over the past eight years, Vicky has helped design and build a handheld microscope that lets you measure wool fibre diameter right there in the yards or shed. Instead of waiting for lab results, you clip a small sample, take a few quick images along the staple, and within seconds, the device tells you the mean micron, standard deviation, coefficient of variation, and comfort factor.You can scan the sheep's ear tag so the data is linked instantly, meaning decisions on classing, culling or breeding can be made on the spot with the most up-to-date information.Vicky and Ferg also chat about the importance of industry collaboration, the current commercialisation of Woven Optics, and the future potential of AI in agriculture.Woven Optics is available now through your local Heiniger representative. Head Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, and Heiniger Australia and New Zealand. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out Heiniger's product range HERECheck out the MSD range HERECheck out Allflex products HERE

Kit Marrs of Alaska Silver, formerly Western Alaska Minerals, provides MSD with a corporate update from the Illinois Creek project in Alaska. Kit talks more about the strategy for its resource estimate in the near future and some thoughts on the gallium mineralization found within its concentrate.

Sandeep Singh, CEO of Western Copper and Gold, provides MSD listeners with a general update on the current process on permitting its Casino project in Yukon.

Checkout ASUS ExpertBook P Series: https://www.flipkart.com/bbd-eb-sale-at-storeGuest Suggestion Form: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://forms.gle/bnaeY3FpoFU9ZjA47⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Disclaimer: This video is intended solely for educational purposes and opinions shared by the guest are his personal views. We do not intent to defame or harm any person/ brand/ product/ country/ profession mentioned in the video. Our goal is to provide information to help audience make informed choices. The media used in this video are solely for informational purposes and belongs to their respective owners.Order 'Build, Don't Talk' (in English) here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://amzn.eu/d/eCfijRu⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Order 'Build Don't Talk' (in Hindi) here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://amzn.eu/d/4wZISO0⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow Our Whatsapp Channel: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.whatsapp.com/channel/0029VaokF5x0bIdi3Qn9ef2J⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Subscribe To Our Other YouTube Channels:-⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@rajshamaniclips⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@RajShamani.Shorts⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

What does leadership look like in agriculture today? For Felicity Taylor, Area Manager for Rabobank in Moree and a 2025 Zanda McDonald Award finalist, it's about connection, community and supporting others to succeed.In this episode, Felicity shares her journey from growing up on a cropping property to becoming the youngest area manager in Rabobank's history. She talks about the rising costs facing farming, the challenge for young people to get started, and why she believes regional Australia offers opportunities that city life cannot. Head Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, and Heiniger Australia and New Zealand. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out Heiniger's product range HERECheck out the MSD range HERECheck out Allflex products HERE

Hugh Agro of Revival Gold joins MSD for a walk-through of the latest met test work done on the sulphide mineralization from Beartrack-Arnett. The company has partnered with the GlasLock Process from Dundee Corporate to find improved contrates of gold and a drastic decrease of the arsenic content. Hugh talks about the technology and next steps of the testing process.

What does it take to keep a sheep business moving forward? For our guest this week, Hamish Thomson of Moojepin Merinos, it's a mix of genetics, management and never being afraid to try something new.In the podcast, Hamish talks about the progress they've made since we spoke to him last, which was four years ago! They have been continuing to select for traits like growth, muscle and fat, as well as intensifying the focus to welfare traits such as dag, worms and, more recently, foot structure. He and Ferg also discuss the importance of ewe lamb joining and using ram lambs, containment feeding, and how they are tackling their most unproductive pastures. Twitter: MoojepinMerinosFacebook: MoojepinMerinosHead Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, and Heiniger Australia and New Zealand. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out Heiniger's product range HERECheck out the MSD range HERECheck out Allflex products HERE

Here it is, the first of our new series called GU Cast Journal Club! A dedicated GU Cast Journal Club has been suggested by many of our listeners and viewers over the years, and we are really pleased to kick off today with the first monthly episode. And we are particularly pleased to introduce our GU Cast Journal Club Editors, Dr Carlso Delgado (Melbourne, AUS), and Dr Elena Berg (Munich, GER). Declan Murphy is anchoring today's episode while Renu is busy elsewhere. Each month, two papers will be discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU OncologyThe objective is to draw attention to important papers in GU Oncology, and critique these in a robust mannerThe key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series. For this inaugural epsiode, we have selected two very important recent papers:1. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GÖTEBORG-1 Trial 2. Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer GU Cast Journal Club is supported by our Partner, MSD, through an unrestricted educational grant. 

Magna Mining's CEO Jason Jessup joins MSD today for his corporate commentary on this morning's drill results out of the Levack Mine. The company drilled into the R2 system, underneath known mineralization encountered earlier this summer. The results returned high-grade base and precious metals which are moving the stock into new all-time high territory.

Our co-host, Ramona Dallum, is joined by Zonetta English, Project Delivery Director at Louisville MSD. MSD is the regional utility for safe, clean waterways, providing quality wastewater, stormwater, and flood protection services. The duo discusses the current work of the utility, flood response, disaster preparedness, and lessons from Hurricane Katrina.English graduated with a BS in Chemistry from UK and a Masters in Business Administration, Concentration in Management and Finance. She also holds a certificate from the Design Build Institute of America.

Kai Hoffman of Soar Financial joins the MSD airwaves for some spirited commentary on the mining and exploration market. Despite gold mostly flat today, the miners and developers continue to outperform with a few specific equities are breaking out to the upside. We also highlight the Deutsche Goldmesse happening this November in Frankfurt. You can find information about the event HERE.

Brock Colterjohn, CEO of Onyx Gold, joins MSD for a walkthrough of the company and their latest drill results coming out of the Argus North target at the Munro-Croesus Project near Timmins, Ontario. Brock walks about the years of work it took the company to consolidate the ground, the process of discovering the Argus North target, and managing the company's equity as a darling of these recent markets in gold exploration.

MSD connects with Brixton Metals once again to discuss their strategic shift towards shallow drilling and a balanced commodity focus. CEO Gary Thompson joins us to discuss the company's approach at the Thorn project, where 50% of the budget targets gold and the other 50% copper. Discover how this strategy is unlocking high-grade mineralization near the surface and what it means for the future of the Camp Creek and Glenfinish zones.

Isaac Maresky of Gold Hart Copper joins MSD to discuss the first drill result out of the Tolita project in Chile. The hole returned 203.5m of 0.25g/t gold equivalent from 137.5m, including a higher grade zone of 67m at 0.38g/t gold equivalent. Later in this same hole, Gold Hart intercepted another 118m of 0.24g/t gold equivalent, including 45.5m at 0.30g/t gold equivalent. Isaac shares some thoughts on the pending results for the next hole into the project.